# A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

> **NCT04492033** · PHASE1,PHASE2 · TERMINATED · sponsor: **Handok Inc.** · enrollment: 41 (actual)

## Conditions studied

- P1b: Advanced Solid Tumors
- P2: Biliary Tract Cancer

## Interventions

- **DRUG:** CTX-009 (ABL001)
- **DRUG:** Paclitaxel
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT04492033
- **Lead sponsor:** Handok Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-22
- **Primary completion:** 2024-01-08
- **Final completion:** 2025-01-09
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Change of Development Plan
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492033, "A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04492033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*